Last $26.55 USD
Change Today +0.11 / 0.42%
Volume 630.0K
TRNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

tornier nv (TRNX) Snapshot

Open
$26.39
Previous Close
$26.44
Day High
$26.81
Day Low
$26.24
52 Week High
10/31/14 - $28.53
52 Week Low
05/1/14 - $16.68
Market Cap
1.3B
Average Volume 10 Days
329.6K
EPS TTM
$-0.55
Shares Outstanding
48.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TORNIER NV (TRNX)

tornier nv (TRNX) Related Businessweek News

No Related Businessweek News Found

tornier nv (TRNX) Details

Tornier N.V., a medical device company, designs, manufactures, markets, and sells orthopedic products. It offers a portfolio of approximately 95 products, including joint replacement, trauma, sports medicine, and biologic products to treat extremity joints. The company also provides joint replacement products for hip and knee. It principally serves surgeons who treat musculoskeletal injuries; and disorders of the shoulder, elbow, hand, wrist, ankle, and foot. The company distributes and sells its products through approximately 145 direct sales representatives and 40 independent sales agencies in the United States; and 13 direct sales offices and 25 distributors in approximately 45 countries worldwide. Tornier N.V. is headquartered in Amsterdam, the Netherlands.

1,076 Employees
Last Reported Date: 02/21/14

tornier nv (TRNX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $444.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $354.4K
Senior Vice President of International Commer...
Total Annual Compensation: $366.3K
Senior Vice President of U.S. Commercial Oper...
Total Annual Compensation: $358.8K
Chief Legal Officer, Senior Vice President an...
Total Annual Compensation: $285.7K
Compensation as of Fiscal Year 2013.

tornier nv (TRNX) Key Developments

Tornier N.V. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 04:00 PM

Tornier N.V. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 04:00 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: David H. Mowry, Chief Executive Officer, President and Executive Director, Shawn T. McCormick, Chief Financial Officer and Principal Accounting Officer.

Tornier N.V. Reports Earnings Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 28, 2014; Reiterates Earnings Guidance for the Fourth Quarter and Full Year Ending December 28, 2014

Tornier N.V. reported earnings unaudited consolidated earnings results for the third quarter and nine months ended September 28, 2014. For the quarter, the company reported non-GAAP EBITDA was $5.766 million against $5.087 million a year ago. Operating loss was $4.425 million against $3.745 million a year ago. Loss before income taxes was $5.798 million against $5.349 million a year ago. Net loss was $5.321 million against $6.292 million a year ago. Net loss per basic and diluted share was $0.11 against $0.13 a year ago. Net cash used in operating activities was $4.622 million against net cash provided by operating activities of $0.580 million a year ago. Purchases of property, plant and equipment was $3.248 million against $2.740 million a year ago. Non-GAAP adjusted EBITDA was $4.046 million against $4.811 million a year ago. Non-GAAP adjusted net loss was 9.820 million against $8.743 million a year ago. Non-GAAP adjusted net loss per basic and diluted share was $0.20 against $0.18 a year ago. Negative non-GAAP adjusted free cash flow was $12.084 million against $6.275 million a year ago. For the nine months, the company reported operating loss was $17.409 million against $16.734 million a year ago. Loss before income taxes was $21.422 million against $24.322 million a year ago. Net loss was $21.006 million against $25.727 million a year ago. Net loss per basic and diluted share was $0.43 against $0.57 a year ago. Net cash used in operating activities was $4.517 million against net cash provided by operating activities of $18.321 million a year ago. Purchases of property, plant and equipment was $8.128 million against $7.518 million a year ago. Non-GAAP EBITDA was $13.010 million against $8.054 million a year ago. Non-GAAP adjusted EBITDA was $19.637 million against $21.275 million a year ago. Non-GAAP adjusted net loss was $21.876 million against $19.017 million a year ago. Non-GAAP adjusted net loss per basic and diluted share was $0.45 against $0.42 a year ago. Negative non-GAAP adjusted free cash flow was $31.394 against $5.762 a year ago. The company is reiterating its previously announced earnings guidance for the fourth quarter ending December 28, 2014, with constant currency revenue expected to be in the range of $85.0 to $89.0 million, representing constant currency growth of 1.9% to 6.7% over the same period last year. Based on recent currency exchange rates, fourth quarter 2014 reported revenue is projected to be in the range of $83.0 to $87.0 million, representing growth of negative 0.4% to positive 4.3% over the same period last year. The company projects fourth 2014 adjusted EBITDA to be in the range of $7.9 to $9.9 million, or 9.5% to 11.4% of reported revenue. The company expects operating loss between $14.6 million to $8.3 million. The company is reiterating earnings guidance for the full year ending December 28, 2014, with constant currency revenue expected to be in the range of $334.9 to $338.9 million, representing an increase of 7.7% to 9.0% over last year. Based on recent currency exchange rates, 2014 reported revenue is projected to be in the range of $335.6 to $339.5 million, representing an increase of 7.9% to 9.2% over last year. The company projects 2014 adjusted EBITDA to be in the range of $27.5 to $29.5 million, or 8.2% to 8.7% of reported revenue. The company expects operating loss between $32.1 million to $25.8 million. The company announced amortization expenses are estimated to be approximately $17.1 million to $17.3 million in 2014 compared to $15.9 million in 2013. The company anticipates interest expense for fiscal 2014 to be in the range of $5.2 million to $5.4 million.

Tornier N.V. Reports Unaudited Revenue Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Revenue Guidance for the Fourth Quarter and Full Year of 2014

Tornier N.V. reported unaudited revenue results for the third quarter and nine months ended September 30, 2014. For the quarter, revenue totaled $76.7 million, compared to third quarter 2013 revenue of $66.7 million, an increase of 14.9% as reported and 14.0% in constant currency. For the nine months, total revenue was $252,550,000 against $227,567,000 a year ago. For the fourth quarter of 2014, the company projects constant currency revenue to be in the range of $85.0 to $89.0 million, representing constant currency growth of 1.9% to 6.7% over the same period last year. Based on recent currency exchange rates, fourth quarter 2014 reported revenue is projected to be in the range of $83.0 to $87.0 million, representing growth of negative 0.4% to positive 4.3% over the same period last year. Revenue from extremities product categories in the fourth quarter of 2014 is expected to be in the range of $70.5 to $73.5 million, representing constant currency growth of 3.5% to 7.9% over the same period last year. For the full year of fiscal 2014, the company is increasing full year guidance and now projects 2014 constant currency revenue to be in the range of $334.9 to $338.9 million, representing an increase of 7.7% to 9.0% over last year. Based on recent currency exchange rates, 2014 reported revenue is projected to be in the range of $335.6 to $339.5 million, representing an increase of 7.9% to 9.2% over last year. Revenue from Tornier's extremities product categories in 2014 is expected to be in the range of $278.8 to $281.8 million, representing an increase in constant currency of 8.1% to 9.2% over last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRNX:US $26.55 USD +0.11

TRNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cyberonics Inc $55.56 USD +0.91
ICU Medical Inc $83.77 USD -0.18
Merit Medical Systems Inc $16.80 USD -0.23
Thoratec Corp $32.64 USD +0.03
Wright Medical Group Inc $27.85 USD -0.17
View Industry Companies
 

Industry Analysis

TRNX

Industry Average

Valuation TRNX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TORNIER NV, please visit www.tornier.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.